No Data
Juno Biomedical (688076.SH): The actual controlling shareholder proposes a mid-term dividend.
On July 17th, Gelunhui reported that Notai Biological (688076.SH) received a letter from its controlling shareholder and actual controller, Mr. Zhao Dezhong, proposing the implementation of mid-term dividends for Jiangsu Notai Ausino Biopharmaceutical Co., Ltd. in 2024. Based on comprehensive considerations such as confidence in the company's long-term development, financial prospects, shareholder interests, etc., it promotes all shareholders to share the fruits of the company's operations and development, and effectively protects the interests of the broad investors. Mr. Zhao Dezhong, the controlling shareholder and actual controller of the company, proposed that the company's board of directors should as soon as possible, within the scope of authorization by the shareholders' meeting, implement the mid-term dividend after the conditions for it have been met.
Are Strong Financial Prospects The Force That Is Driving The Momentum In Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s SHSE:688076) Stock?
Sinopep-Allsino Biopharmaceutical's Plant Passes Regulatory Inspection
Nuocheng Bio (688076.SH): the new oral solid preparation workshop and hard capsule production line passed the pharmaceutical GMP compliance inspection.
Notech Biotechnology (688076.SH) announced that its 203 workshop at the China Medicine Port plant has been inspected for compliance with FDA/EM...
The actual controller and its concerted parties of Neutai Bio (688076.SH) have cumulatively reduced their shareholding of 660,000 shares of "Neutai Convertible Bonds".
Noted on July 2, Gelonghui: Notable Bio (688076.SH) announced that it has recently received a notice from the controlling shareholder and actual controller. It was learned that the actual controllers Zhao Deyi and Zhao Dezhong and their concerted actions will reduce their holdings of 660,000 "Note Bond" instruments between July 1 and July 2, 2024 through the Shanghai Stock Exchange system, accounting for 15.21% of the total issuance of "Note Bond".
Notable Biology (688076.SH): Intends to use the raised funds of 31.9184 million yuan for the implementation of the active pharmaceutical ingredient product development project.
On June 26th, Gelunhui announced that Nova Bio (688076.SH) held its 20th meeting of the third board of directors and the 17th meeting of the third supervisor board on June 26th, 2024. They approved the proposal on using part of the raised funds to increase the capital of wholly-owned subsidiary for implementing the raised investment project. The company agreed to use 31,918,400 yuan of the raised funds to implement the "active pharmaceutical ingredient R&D project". The company will provide 31,918,400 yuan of raised funds to Hangzhou Nova Biomedical Technology Co., Ltd. ("Nova") by increasing its capital. After the capital increase is completed this time,
Earnings Not Telling The Story For Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (SHSE:688076) After Shares Rise 26%No Data
